The announcement of positive pre-clinical results is typically seen as a positive development for biotech companies, as it indicates progress in their research and development efforts. This can lead to increased investor optimism about the company's future prospects, particularly in the lucrative markets for obesity and diabetes treatments. However, as these are pre-clinical results, there is still uncertainty regarding the treatment's efficacy in humans and the timeline for commercialization, which tempers the confidence score slightly.